Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
MK-8242 binds MDM2 and prevents its interaction with p53, thereby inhibiting degradation of p53 and potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MK-8242||SCH 900242||MDM2 Inhibitor 19||MK-8242 binds MDM2 and prevents its interaction with p53, thereby inhibiting degradation of p53 and potentially resulting in increased tumor cell apoptosis (PMID: 30253242).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||MK-8242||Phase I||Actionable||In a Phase I trial, MK-8242 demonstrated safety and some preliminary efficacy in patients with refractory or recurrent acute myeloid leukemia, with 3 out of 24 evaluable patients demonstrating an objective response (PMID: 27544076).||27544076|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|